



September 22, 2026

BSE Limited,
P J Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524735

National Stock Exchange of India Limited,
Exchange Plaza,
Bandra-Kurla Complex, Bandra,
Mumbai - 400 051.
Symbol: HIKAL

Dear Sir/Madam,

Subject: Press Release- Hikal ventures into personal care: New cGMP Panoli facility begins Commercial Production.

Please find enclosed herewith, a copy of the press release titled “Hikal ventures into personal care: New cGMP Panoli facility begins Commercial Production”.

This is for your information and records.

Thank you,

Yours Sincerely,
For **Hikal Limited,**

Rajasekhar Reddy
Company Secretary & Compliance Officer

Encl: As above

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717/718, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028



Hikal ventures into Personal Care: New cGMP Panoli Facility Begins Commercial Production

New multipurpose facility marks Hikal's entry into commercial-scale Personal Care manufacturing, with second-generation UV filters and a growing pipeline of global and domestic partnerships

Mumbai, 22 September, 2026: Hikal Limited, a trusted global partner in Pharmaceuticals, Crop Protection and Animal Health segment, today announced the successful commercial production of its Personal Care products, following the commissioning of its new cGMP-compliant, multipurpose manufacturing facility dedicated to this business at its Panoli, Gujarat site. The milestone marks Hikal's formal entry into commercial-scale supply for the global beauty and personal care industry and represents the latest step in the Company's broader strategy of building new, high-value growth platforms alongside its established Pharmaceuticals, Crop Protection and growing Animal Healthcare business.

As part of its strategic commitment to this new segment, Hikal repurposed an existing manufacturing asset at Panoli to serve the evolving needs of the global beauty and personal care industry, bringing the Company's decades of process chemistry and regulatory manufacturing experience to a new customer base.

The facility has commenced commercial production recently, and successfully manufactured its first production batches. Product samples have since been validated with customers, and the Company has received encouraging feedback, resulting in a positive market pull for its product portfolio.

Hikal's initial focus within Personal Care is on the Beauty & Personal Care segment, particularly the skin care category, where demand continues to grow globally. The Company has built a strong portfolio of second-generation UV filters, offering enhanced performance and closer alignment with evolving consumer preferences and tightening regulatory requirements across key markets.

These products are undergoing approvals by its global customers, as part of Hikal's continued strategy of portfolio diversification beyond its core Pharma and Crop Protection segments.

"Personal Care represents the kind of long-term opportunity we look for. We've applied the same disciplined approach that built our Pharmaceuticals and Crop Protection businesses, deep customer partnerships, rigorous quality systems and patient capital investment, to a new category where global demand for specialty skincare ingredients is accelerating. Commissioning the Panoli facility, manufacturing our first production batches, and securing positive customer feedback points towards the growth of the business in the coming years," said, Sameer Hiremath, Vice Chairman & Managing Director, Hikal Limited

This latest facility adds to a broader pattern of capability-building across Hikal's platform. Recently the Company also commissioned a new cGMP pilot plant at its Pune Research & Technology campus to strengthen pharmaceutical process development and scale-up capabilities which will help in growing the CDMO business.

The announcement also follows Hikal's recent EcoVadis Gold Medal rating for sustainability excellence, placing the Company among the top 5% of more than 175,000 companies assessed globally. With an overall score of 84/100 and a 97th percentile ranking, the recognition reinforces



Hikal's commitment to responsible manufacturing, ethical business practices, sustainable procurement and long-term value creation across its businesses.

About Hikal Limited

Established in 1988, Hikal is a reliable partner to companies in the Pharmaceutical, Animal Health, Biotech, Personal Care and Specialty Chemical industries. We manufacture and supply quality Active Ingredients, Intermediates, Biocides to the global life sciences industry. Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bengaluru (Jigani) and a world-class Research & Technology centre at Pune. Our facilities have been inspected and certified by the Global Regulatory Authorities. We create and deliver sustainable solutions for our partners and customers across the life-sciences value chain.

Hikal believes in inclusive growth that embraces all constituents. Hikal is one of the first Indian life-sciences companies to receive the Responsible Care® certification and has also been awarded the EcoVadis Gold Medal rating, placing it among the top 5% of companies assessed globally for sustainability performance. We accord top priority to the health and safety of our employees by adopting best practices in manufacturing.